0MR5.LSE

CellaVision AB

0MR5.LSE, UK

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.

https://www.cellavision.com

Stock Price

SEK0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2022-12-31)

Health Score

Investors

* Institutions hold a combined 0.00% of the total shares of CellaVision AB

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.83

Latest Release

Date

2025-09-30

EPS Actual

1.3139

EPS Estimate

1.43

EPS Difference

-0.1161

Surprise Percent

-8.1189%

Investing Fit Scorecard

(Last Updated 2022-12-31)

Deep Value
Weak Deep Value(0.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1.5)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2022-12-31)

Revenue

SEK 0

Cost Of Revenue

SEK 0

Gross Profit

SEK 0

Operating Expenses

SEK 0

Operating Income

SEK 0

Interest Expense

SEK 0

Pretax Income

SEK 0

Net Income

SEK 0

Income Tax Expense

SEK 0

EBITDA

SEK 0

Total Other Income Expense Net

SEK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2022-12-31)

Cash

SEK 0

Short Term Investments

SEK 0

Receivables

SEK 0

Inventories

SEK 0

Total Current Assets

SEK 0

Property Plant Equipment

SEK 0

Total Assets

SEK 0

Payables

SEK 0

Short Term Debt

SEK 0

Long Term Debt

SEK 0

Total Liabilities

SEK 0

Equity

SEK 0

Trend

Cash Flow

(Last Updated 2022-12-31)

Net Income

SEK 0

Depreciation

SEK 0

Change In Working Capital

SEK 0

Cash From Operations

SEK 0

Capital Expenditures

SEK 0

Cash From Investing

SEK 0

Cash From Financing

SEK 0

Net Change In Cash

SEK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.